Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation

Recruiting now · Phase 3

Conditions studied: Engraftment Syndrome

In brief

The purpose of this study is to determine if budesonide prophylaxis starting day 5 after transplant reduces engraftment fever in autologous and allogeneic stem cell transplant recipients.

Key facts

Study ID

NCT05509933

Run by

Henry Ford Health System

People needed

110

Starts

2022-11-09

Expected to finish

2027-12-30

Last updated by the study team

2026-05-01

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• • Patients 18-80 years of age with a diagnosis of a hematological malignancy
• Meet the BMT program criteria to undergo hematopoietic stem cell transplantation for hematologi malignancies

You may not qualify if…

• • Patients enrolled in investigational clinical trials
• Sct for non hematologic malignancies

Where it is running

• Henry Ford Health System — Detroit, Michigan, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.